Cushing's disease is a disorder characterized by supraphysiologic levels of circulating cortisol due to excessive adrenocorticotropic hormone (ACTH) secretion. Most often hypersecretion of ACTH is due to a pituitary adenoma, where surgical resection of the tumor is considered first-line treatment for the disease. Alternatively, the FDA has recently approved the somatostatin analogue, Signifor® (pasireotide), for the management of Cushing's disease in patients for whom surgery is not an option. In clinical trials, pasireotide has shown a statistically significant reduction in urinary free cortisol levels, as well as significant improvements in quality of life. Based on current data, pasireotide appears to offer a new potential treatment option for patients who are poor candidates for surgery.
Steele J, Ruhe A, Skouby A, Stack E, Hrometz SL. Signifor® Receives FDA Approvalfor the Management of Cushing's Disease. PAW Review. 2013 May 01; 4(2):Article 14 67-70 . Available from: https://digitalcommons.onu.edu/paw_review/vol4/iss2/14.